Pharmas spending too much on buybacks, not enough on big deals: report | BioPharma Dive https://t.co/xBKFzfZ9S6
— The Propell Group (@ThePropellGroup) January 8, 2019
Pharmas spending too much on buybacks, not enough on big deals: report | BioPharma Dive https://t.co/xBKFzfZ9S6
— The Propell Group (@ThePropellGroup) January 8, 2019